EXICURE INC (XCUR) Stock News

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Why Exicure Inc. (XCUR) Soared on Monday

We recently compiled a list of the 10 Micro-, Small-Cap Companies Lead Monday’s Charge. In this article, we are going to take a look at where Exicure Inc. (NASDAQ:XCUR) stands against the other stocks. The stock market ended the first trading day of the week in the negative territory, with all major indices recording hefty losses, […]

Mentions: TSLA NVDA AAPL

How Is The Market Feeling About Exicure?

Reneo Pharmaceuticals And 2 Other Stocks Under $5 Executives Are Buying

Mentions: AMLX RPHM

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

Exicure, Inc. Reports Full Year 2024 Financial Results

Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia

Exicure Stock Soars Over 25% On Acquisition Of GPCR Therapeutics’ U.S. Unit: Retail Chatter Spikes

GPCR USA is noted for its work in developing cutting-edge treatments, including Opdivo, a widely used autoimmune disease therapy generating about $10 billion in annual revenue.

CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech

CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results

Exicure, Inc. Receives Extension from Nasdaq Hearings Panel